Cargando…

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

BACKGROUND: Tyrosine kinase inhibitors, such as crizotinib and erlotinib, are widely used to treat non-small-cell lung cancer, but after initial response, relapse is common because of the emergence of resistance through multiple mechanisms. Here, we investigated whether a frontline combination with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Courtin, Aurelie, Smyth, Tomoko, Hearn, Keisha, Saini, Harpreet K, Thompson, Neil T, Lyons, John F, Wallis, Nicola G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117788/ https://www.ncbi.nlm.nih.gov/pubmed/27673365 http://dx.doi.org/10.1038/bjc.2016.294

Ejemplares similares

Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2020)

Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
por: Mortensen, Anja Charlotte Lundgren, et al.
Publicado: (2023)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

The HSP90 inhibitor onalespib potentiates (177)Lu-DOTATATE therapy in neuroendocrine tumor cells
por: Lundsten, Sara, et al.
Publicado: (2019)

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
por: Wu, X, et al.
Publicado: (2009)

Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
por: Stingl, L, et al.
Publicado: (2010)

The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach
por: Spiegelberg, Diana, et al.
Publicado: (2020)

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer
por: Lee, S J, et al.
Publicado: (2014)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
por: Jin, L, et al.
Publicado: (2011)

Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation
por: Zhang, Y, et al.
Publicado: (2014)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
por: Xu, W, et al.
Publicado: (2007)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
por: Kang, B H, et al.
Publicado: (2011)

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer
por: Li, Meng, et al.
Publicado: (2017)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
por: Loriot, Y, et al.
Publicado: (2010)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate
por: Khanim, F, et al.
Publicado: (2014)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

HDAC inhibitor confers radiosensitivity to prostate stem-like cells
por: Frame, F M, et al.
Publicado: (2013)

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
por: Coley, H M, et al.
Publicado: (2012)

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
por: Chang, J, et al.
Publicado: (2012)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
por: Mohammed, M Z, et al.
Publicado: (2011)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo
por: Gibert, B, et al.
Publicado: (2012)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types
por: Green, S R, et al.
Publicado: (2010)

γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
por: Mizugaki, H, et al.
Publicado: (2012)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
por: Meira, D D, et al.
Publicado: (2009)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7ma5ldgpud90a0f4soucq89ec2